BackgroundIdentification of fatigue in people with Multiple Sclerosis (pwMS) is still mainly based on subjective assessments due to the lack of objective diagnostic tools. We aimed to identify vocal biomarkers to differentiate between pwMS with and without fatigue.MethodsThis COMMITMENT trial was a prospective, observational study recruiting healthy controls (HCs, n = 20) and relapsing MS (RMS) patients (n = 50, EDSS <4.0) at University Hospital of Bern. The primary objective was to predict fatigue in pwMS by means of automated artificial intelligence (AI)-based speech analysis. An exploratory objective was to differentiate between pwMS and HCs.FindingsParticipants had a mean age of 36.0 years, and 73% were female, with no significant group differences. Median EDSS in pwMS was 1.0 (range 0–3.0). Motor fatigue affected 50% and cognitive fatigue 40% of pwMS. Five acoustic features were associated with general fatigue, independently of depression and sleepiness. Further, five features were associated with motor-, and 12 with cognitive fatigue. The best-performing classification and regression models [Leave-One-Speaker-Out (LOSO) paradigm] achieved specificities of 0.68–0.94, whereas sensitivity remained lower (0.38–0.90). Speech biomarkers distinguished pwMS from HCs with a specificity of 0.90 but only a sensitivity of 0.3.InterpretationSpeech in pwMS may serve as a potential biomarker for MS-associated fatigue and might help to differentiate between pwMS and HC. Our findings suggest that AI-assisted speech analysis could complement existing fatigue assessments.
Digital first primary care in NHS England: evaluating alignment with patient-centered care and implications for future practice
The Digital First Primary Care (DFPC) model, introduced by NHS England, aims to enhance healthcare accessibility and efficiency by leveraging digital tools such as telemedicine,